{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:04:37Z","timestamp":1793639077306,"version":"4.5.1"},"reference-count":185,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA285515"],"award-info":[{"award-number":["R01CA285515"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA285515"],"award-info":[{"award-number":["R01CA285515"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Genotoxic anticancer therapies exploit the heightened DNA replication stress of cancer cells. Members of the phosphoinositide-3-kinase-related kinase (PIKK) family, including ATR, ATM and DNA-PKcs, orchestrate the DNA damage response at stalled and broken replication forks, triggering complex signaling cascades that dictate cell fate. p53 plays a pivotal role in regulating the processes of cell cycle, DNA repair and programmed cell death, although p53-independent regulatory mechanisms are also evident. Genotoxic drugs often induce therapy-induced senescence, a state of dynamic and reversible cytostasis that promotes drug resistance and unfavorable patient outcomes. Conversely, severe replication stress culminates in DNA replication catastrophe, a manifestation of irreversible fork collapse with extensive single-stranded DNA accumulation that ultimately results in cell death. Therefore, the magnitude of DNA replication damage and engaged signal transduction pathways determine the outcome of genotoxic therapy. Understanding the molecular basis of the replication stress response that drives therapy-induced senescence versus cell death has far-reaching implications for enhancing the cytotoxic efficacy of anticancer regimens. Here we review the mechanisms of the DNA replication stress response, focusing on pharmacological interventions designed to shift the balance from survival to cell death.<\/jats:p>","DOI":"10.1038\/s12276-026-01745-9","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T11:37:50Z","timestamp":1780659470000},"page":"1721-1733","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Tilting the balance of life and death: navigating DNA replication stress in cancer therapy"],"prefix":"10.1038","volume":"58","author":[{"given":"Natalie","family":"Lo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1913-6373","authenticated-orcid":false,"given":"Hyungjin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"1745_CR1","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/nrm2858","volume":"11","author":"S Negrini","year":"2010","unstructured":"Negrini, S., Gorgoulis, V. G. & Halazonetis, T. D. Genomic instability\u2014an evolving hallmark of cancer. Nat. Rev. Mol. Cell Biol. 11, 220\u2013228 (2010).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1745_CR2","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.molcel.2010.09.019","volume":"40","author":"A Ciccia","year":"2010","unstructured":"Ciccia, A. & Elledge, S. J. The DNA damage response: making it safe to play with knives. Mol. Cell 40, 179\u2013204 (2010).","journal-title":"Mol. Cell"},{"key":"1745_CR3","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/nature03482","volume":"434","author":"J Bartkova","year":"2005","unstructured":"Bartkova, J. et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434, 864\u2013870 (2005).","journal-title":"Nature"},{"key":"1745_CR4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nrc.2015.2","volume":"16","author":"WP Roos","year":"2016","unstructured":"Roos, W. P., Thomas, A. D. & Kaina, B. DNA damage and the balance between survival and death in cancer biology. Nat. Rev. Cancer 16, 20\u201333 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"1745_CR5","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/nrc3916","volume":"15","author":"H Gaillard","year":"2015","unstructured":"Gaillard, H., Garcia-Muse, T. & Aguilera, A. Replication stress and cancer. Nat. Rev. Cancer 15, 276\u2013289 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"1745_CR6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/nrc2342","volume":"8","author":"T Helleday","year":"2008","unstructured":"Helleday, T., Petermann, E., Lundin, C., Hodgson, B. & Sharma, R. A. DNA repair pathways as targets for cancer therapy. Nat. Rev. Cancer 8, 193\u2013204 (2008).","journal-title":"Nat. Rev. Cancer"},{"key":"1745_CR7","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41556-018-0249-2","volume":"21","author":"S Lee","year":"2019","unstructured":"Lee, S. & Schmitt, C. A. The dynamic nature of senescence in cancer. Nat. Cell Biol. 21, 94\u2013101 (2019).","journal-title":"Nat. Cell Biol."},{"key":"1745_CR8","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/nature08467","volume":"461","author":"SP Jackson","year":"2009","unstructured":"Jackson, S. P. & Bartek, J. The DNA-damage response in human biology and disease. Nature 461, 1071\u20131078 (2009).","journal-title":"Nature"},{"key":"1745_CR9","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","volume":"66","author":"AN Blackford","year":"2017","unstructured":"Blackford, A. N. & Jackson, S. P. ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response. Mol. Cell 66, 801\u2013817 (2017).","journal-title":"Mol. Cell"},{"key":"1745_CR10","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.dnarep.2009.04.006","volume":"8","author":"CA Lovejoy","year":"2009","unstructured":"Lovejoy, C. A. & Cortez, D. Common mechanisms of PIKK regulation. DNA Repair 8, 1004\u20131008 (2009).","journal-title":"DNA Repair"},{"key":"1745_CR11","doi-asserted-by":"publisher","unstructured":"Marechal, A. & Zou, L. DNA damage sensing by the ATM and ATR kinases. Cold Spring Harb. Perspect. Biol. https:\/\/doi.org\/10.1101\/cshperspect.a012716 (2013).","DOI":"10.1101\/cshperspect.a012716"},{"key":"1745_CR12","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1101\/gad.1015202","volume":"16","author":"DW Chan","year":"2002","unstructured":"Chan, D. W. et al. Autophosphorylation of the DNA-dependent protein kinase catalytic subunit is required for rejoining of DNA double-strand breaks. Genes Dev. 16, 2333\u20132338 (2002).","journal-title":"Genes Dev."},{"key":"1745_CR13","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1080\/15384101.2016.1158362","volume":"15","author":"WC Lau","year":"2016","unstructured":"Lau, W. C. et al. Structure of the human dimeric ATM kinase. Cell Cycle 15, 1117\u20131124 (2016).","journal-title":"Cell Cycle"},{"key":"1745_CR14","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.molcel.2011.06.019","volume":"43","author":"S Liu","year":"2011","unstructured":"Liu, S. et al. ATR autophosphorylation as a molecular switch for checkpoint activation. Mol. Cell 43, 192\u2013202 (2011).","journal-title":"Mol. Cell"},{"key":"1745_CR15","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1101\/gad.14.12.1448","volume":"14","author":"Q Liu","year":"2000","unstructured":"Liu, Q. et al. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)\/M DNA damage checkpoint. Genes Dev. 14, 1448\u20131459 (2000).","journal-title":"Genes Dev."},{"key":"1745_CR16","doi-asserted-by":"publisher","first-page":"5195","DOI":"10.1093\/emboj\/cdf506","volume":"21","author":"H Takai","year":"2002","unstructured":"Takai, H. et al. Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription. EMBO J. 21, 5195\u20135205 (2002).","journal-title":"EMBO J."},{"key":"1745_CR17","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1101\/gad.10.19.2411","volume":"10","author":"Y Xu","year":"1996","unstructured":"Xu, Y. et al. Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma. Genes Dev. 10, 2411\u20132422 (1996).","journal-title":"Genes Dev."},{"key":"1745_CR18","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1158\/1535-7163.MCT-15-0945","volume":"15","author":"M Choi","year":"2016","unstructured":"Choi, M., Kipps, T. & Kurzrock, R. ATM mutations in cancer: therapeutic implications. Mol. Cancer Ther. 15, 1781\u20131791 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"1745_CR19","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/nrm.2017.67","volume":"18","author":"JC Saldivar","year":"2017","unstructured":"Saldivar, J. C., Cortez, D. & Cimprich, K. A. The essential kinase ATR: ensuring faithful duplication of a challenging genome. Nat. Rev. Mol. Cell Biol. 18, 622\u2013636 (2017).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1745_CR20","doi-asserted-by":"publisher","first-page":"4243","DOI":"10.1016\/j.molcel.2021.08.009","volume":"81","author":"Y Yin","year":"2021","unstructured":"Yin, Y. et al. A basal-level activity of ATR links replication fork surveillance and stress response. Mol. Cell 81, 4243\u20134257 (2021).","journal-title":"Mol. Cell"},{"key":"1745_CR21","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S1097-2765(02)00799-2","volume":"11","author":"V Costanzo","year":"2003","unstructured":"Costanzo, V. et al. An ATR- and Cdc7-dependent DNA damage checkpoint that inhibits initiation of DNA replication. Mol. Cell 11, 203\u2013213 (2003).","journal-title":"Mol. Cell"},{"key":"1745_CR22","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1083\/jcb.201007074","volume":"191","author":"XQ Ge","year":"2010","unstructured":"Ge, X. Q. & Blow, J. J. Chk1 inhibits replication factory activation but allows dormant origin firing in existing factories. J. Cell Biol. 191, 1285\u20131297 (2010).","journal-title":"J. Cell Biol."},{"key":"1745_CR23","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41573-022-00558-5","volume":"22","author":"A da Costa","year":"2023","unstructured":"da Costa, A., Chowdhury, D., Shapiro, G. I., D\u2019Andrea, A. D. & Konstantinopoulos, P. A. Targeting replication stress in cancer therapy. Nat. Rev. Drug Discov. 22, 38\u201358 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1745_CR24","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1158\/0008-5472.CAN-19-3126","volume":"80","author":"S Rafiei","year":"2020","unstructured":"Rafiei, S. et al. ATM loss confers greater sensitivity to ATR inhibition than PARP inhibition in prostate cancer. Cancer Res. 80, 2094\u20132100 (2020).","journal-title":"Cancer Res."},{"key":"1745_CR25","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1126\/science.1108297","volume":"308","author":"JH Lee","year":"2005","unstructured":"Lee, J. H. & Paull, T. T. ATM activation by DNA double-strand breaks through the Mre11\u2013Rad50\u2013Nbs1 complex. Science 308, 551\u2013554 (2005).","journal-title":"Science"},{"key":"1745_CR26","doi-asserted-by":"publisher","first-page":"13182","DOI":"10.1073\/pnas.0504211102","volume":"102","author":"Y Sun","year":"2005","unstructured":"Sun, Y., Jiang, X., Chen, S., Fernandes, N. & Price, B. D. A role for the Tip60 histone acetyltransferase in the acetylation and activation of ATM. Proc. Natl Acad. Sci. USA 102, 13182\u201313187 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1745_CR27","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1126\/science.1192912","volume":"330","author":"Z Guo","year":"2010","unstructured":"Guo, Z., Kozlov, S., Lavin, M. F., Person, M. D. & Paull, T. T. ATM activation by oxidative stress. Science 330, 517\u2013521 (2010).","journal-title":"Science"},{"key":"1745_CR28","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1126\/science.1083430","volume":"300","author":"L Zou","year":"2003","unstructured":"Zou, L. & Elledge, S. J. Sensing DNA damage through ATRIP recognition of RPA\u2013ssDNA complexes. Science 300, 1542\u20131548 (2003).","journal-title":"Science"},{"key":"1745_CR29","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1101\/gad.1666208","volume":"22","author":"DA Mordes","year":"2008","unstructured":"Mordes, D. A., Glick, G. G., Zhao, R. & Cortez, D. TopBP1 activates ATR through ATRIP and a PIKK regulatory domain. Genes Dev. 22, 1478\u20131489 (2008).","journal-title":"Genes Dev."},{"key":"1745_CR30","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1101\/gad.1547007","volume":"21","author":"S Delacroix","year":"2007","unstructured":"Delacroix, S., Wagner, J. M., Kobayashi, M., Yamamoto, K. & Karnitz, L. M. The Rad9\u2013Hus1\u2013Rad1 (9\u20131\u20131) clamp activates checkpoint signaling via TopBP1. Genes Dev. 21, 1472\u20131477 (2007).","journal-title":"Genes Dev."},{"key":"1745_CR31","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1038\/ncb3422","volume":"18","author":"P Haahr","year":"2016","unstructured":"Haahr, P. et al. Activation of the ATR kinase by the RPA-binding protein ETAA1. Nat. Cell Biol. 18, 1196\u20131207 (2016).","journal-title":"Nat. Cell Biol."},{"key":"1745_CR32","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/ncb3415","volume":"18","author":"TE Bass","year":"2016","unstructured":"Bass, T. E. et al. ETAA1 acts at stalled replication forks to maintain genome integrity. Nat. Cell Biol. 18, 1185\u20131195 (2016).","journal-title":"Nat. Cell Biol."},{"key":"1745_CR33","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1126\/science.aap9346","volume":"361","author":"JC Saldivar","year":"2018","unstructured":"Saldivar, J. C. et al. An intrinsic S\/G(2) checkpoint enforced by ATR. Science 361, 806\u2013810 (2018).","journal-title":"Science"},{"key":"1745_CR34","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.celrep.2013.10.027","volume":"5","author":"JK Eykelenboom","year":"2013","unstructured":"Eykelenboom, J. K. et al. ATR activates the S-M checkpoint during unperturbed growth to ensure sufficient replication prior to mitotic onset. Cell Rep. 5, 1095\u20131107 (2013).","journal-title":"Cell Rep."},{"key":"1745_CR35","doi-asserted-by":"publisher","unstructured":"Yue, X., Bai, C., Xie, D., Ma, T. & Zhou, P. K. DNA-PKcs: a multi-faceted player in DNA damage response. Front. Genet. https:\/\/doi.org\/10.3389\/fgene.2020.607428 (2020).","DOI":"10.3389\/fgene.2020.607428"},{"key":"1745_CR36","doi-asserted-by":"publisher","first-page":"3932","DOI":"10.1016\/j.molcel.2022.08.028","volume":"82","author":"D Dibitetto","year":"2022","unstructured":"Dibitetto, D. et al. DNA-PKcs promotes fork reversal and chemoresistance. Mol. Cell 82, 3932\u20133942.e3936 (2022).","journal-title":"Mol. Cell"},{"key":"1745_CR37","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.dnarep.2014.04.008","volume":"21","author":"AK Ashley","year":"2014","unstructured":"Ashley, A. K. et al. DNA-PK phosphorylation of RPA32 Ser4\/Ser8 regulates replication stress checkpoint activation, fork restart, homologous recombination and mitotic catastrophe. DNA Repair 21, 131\u2013139 (2014).","journal-title":"DNA Repair"},{"key":"1745_CR38","doi-asserted-by":"publisher","first-page":"10780","DOI":"10.1093\/nar\/gks849","volume":"40","author":"S Liu","year":"2012","unstructured":"Liu, S. et al. Distinct roles for DNA-PK, ATM and ATR in RPA phosphorylation and checkpoint activation in response to replication stress. Nucleic Acids Res. 40, 10780\u201310794 (2012).","journal-title":"Nucleic Acids Res."},{"key":"1745_CR39","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1093\/emboj\/18.5.1397","volume":"18","author":"RG Shao","year":"1999","unstructured":"Shao, R. G. et al. Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA:DNA-PK complexes. EMBO J. 18, 1397\u20131406 (1999).","journal-title":"EMBO J."},{"key":"1745_CR40","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.molcel.2015.07.029","volume":"59","author":"R Buisson","year":"2015","unstructured":"Buisson, R., Boisvert, J. L., Benes, C. H. & Zou, L. Distinct but concerted roles of ATR, DNA-PK, and Chk1 in countering replication stress during S phase. Mol. Cell 59, 1011\u20131024 (2015).","journal-title":"Mol. Cell"},{"key":"1745_CR41","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.dnarep.2018.08.021","volume":"71","author":"AD D\u2019Andrea","year":"2018","unstructured":"D\u2019Andrea, A. D. Mechanisms of PARP inhibitor sensitivity and resistance. DNA Repair 71, 172\u2013176 (2018).","journal-title":"DNA Repair"},{"key":"1745_CR42","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.trecan.2024.06.008","volume":"10","author":"D Dibitetto","year":"2024","unstructured":"Dibitetto, D., Widmer, C. A. & Rottenberg, S. PARPi, BRCA, and gaps: controversies and future research. Trends Cancer 10, 857\u2013869 (2024).","journal-title":"Trends Cancer"},{"key":"1745_CR43","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1016\/j.molcel.2022.04.023","volume":"82","author":"K Cong","year":"2022","unstructured":"Cong, K. & Cantor, S. B. Exploiting replication gaps for cancer therapy. Mol. Cell 82, 2363\u20132369 (2022).","journal-title":"Mol. Cell"},{"key":"1745_CR44","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.molcel.2018.06.004","volume":"71","author":"H Hanzlikova","year":"2018","unstructured":"Hanzlikova, H. et al. The importance of poly(ADP-ribose) polymerase as a sensor of unligated Okazaki fragments during DNA replication. Mol. Cell 71, 319\u2013331(2018).","journal-title":"Mol. Cell"},{"key":"1745_CR45","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41594-022-00747-1","volume":"29","author":"A Vaitsiankova","year":"2022","unstructured":"Vaitsiankova, A. et al. PARP inhibition impedes the maturation of nascent DNA strands during DNA replication. Nat. Struct. Mol. Biol. 29, 329\u2013338 (2022).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"1745_CR46","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1016\/j.molcel.2021.06.011","volume":"81","author":"K Cong","year":"2021","unstructured":"Cong, K. et al. Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency. Mol. Cell 81, 3128\u20133144 (2021).","journal-title":"Mol. Cell"},{"key":"1745_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33028-y","volume":"13","author":"T Thakar","year":"2022","unstructured":"Thakar, T. et al. Lagging strand gap suppression connects BRCA-mediated fork protection to nucleosome assembly through PCNA-dependent CAF-1 recycling. Nat. Commun. 13, 5323 (2022).","journal-title":"Nat. Commun."},{"key":"1745_CR48","doi-asserted-by":"publisher","first-page":"4026","DOI":"10.1016\/j.molcel.2021.09.013","volume":"81","author":"S Tirman","year":"2021","unstructured":"Tirman, S. et al. Temporally distinct post-replicative repair mechanisms fill PRIMPOL-dependent ssDNA gaps in human cells. Mol. Cell 81, 4026\u20134040 (2021).","journal-title":"Mol. Cell"},{"key":"1745_CR49","doi-asserted-by":"publisher","first-page":"4692","DOI":"10.1016\/j.molcel.2021.09.005","volume":"81","author":"M Paes Dias","year":"2021","unstructured":"Paes Dias, M. et al. Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1\/53BP1 double-deficient cells by exposing ssDNA gaps. Mol. Cell 81, 4692\u20134708 (2021).","journal-title":"Mol. Cell"},{"key":"1745_CR50","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/10409238.2020.1841089","volume":"56","author":"S Tirman","year":"2021","unstructured":"Tirman, S., Cybulla, E., Quinet, A., Meroni, A. & Vindigni, A. PRIMPOL ready, set, reprime! Crit. Rev. Biochem. Mol. Biol. 56, 17\u201330 (2021).","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"1745_CR51","doi-asserted-by":"publisher","first-page":"4664","DOI":"10.1016\/j.molcel.2022.11.008","volume":"82","author":"O Belan","year":"2022","unstructured":"Belan, O. et al. POLQ seals post-replicative ssDNA gaps to maintain genome stability in BRCA-deficient cancer cells. Mol. Cell 82, 4664\u20134680(2022).","journal-title":"Mol. Cell"},{"key":"1745_CR52","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1016\/j.molcel.2022.09.013","volume":"82","author":"A Mann","year":"2022","unstructured":"Mann, A. et al. POLtheta prevents MRE11-NBS1-CtIP-dependent fork breakage in the absence of BRCA2\/RAD51 by filling lagging-strand gaps. Mol. Cell 82, 4218\u20134231 (2022).","journal-title":"Mol. Cell"},{"key":"1745_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111716","volume":"41","author":"A Schrempf","year":"2022","unstructured":"Schrempf, A. et al. POLtheta processes ssDNA gaps and promotes replication fork progression in BRCA1-deficient cells. Cell Rep. 41, 111716 (2022).","journal-title":"Cell Rep."},{"key":"1745_CR54","doi-asserted-by":"publisher","unstructured":"Patel, J. A. et al. The DNA-PKcs\/JNK\/p53 pathway underlies changes in cell fate decision toward death during DNA replication catastrophe. Nucleic Acids Res. https:\/\/doi.org\/10.1093\/nar\/gkaf573 (2025).","DOI":"10.1093\/nar\/gkaf573"},{"key":"1745_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51667-1","volume":"15","author":"Z Machacova","year":"2024","unstructured":"Machacova, Z., Chroma, K., Lukac, D., Protivankova, I. & Moudry, P. DNA polymerase alpha-primase facilitates PARP inhibitor-induced fork acceleration and protects BRCA1-deficient cells against ssDNA gaps. Nat. Commun. 15, 7375 (2024).","journal-title":"Nat. Commun."},{"key":"1745_CR56","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.molcel.2020.12.010","volume":"81","author":"MM Genois","year":"2021","unstructured":"Genois, M. M. et al. CARM1 regulates replication fork speed and stress response by stimulating PARP1. Mol. Cell 81, 784\u2013800 (2021).","journal-title":"Mol. Cell"},{"key":"1745_CR57","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1101\/gad.348479.121","volume":"35","author":"A Simoneau","year":"2021","unstructured":"Simoneau, A., Xiong, R. & Zou, L. The trans cell cycle effects of PARP inhibitors underlie their selectivity toward BRCA1\/2-deficient cells. Genes Dev. 35, 1271\u20131289 (2021).","journal-title":"Genes Dev."},{"key":"1745_CR58","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.molcel.2023.12.025","volume":"84","author":"PX Lim","year":"2024","unstructured":"Lim, P. X., Zaman, M., Feng, W. & Jasin, M. BRCA2 promotes genomic integrity and therapy resistance primarily through its role in homology-directed repair. Mol. Cell 84, 447\u2013462(2024).","journal-title":"Mol. Cell"},{"key":"1745_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.dnarep.2021.103209","volume":"107","author":"SB Cantor","year":"2021","unstructured":"Cantor, S. B. Revisiting the BRCA-pathway through the lens of replication gap suppression: \u201cGaps determine therapy response in BRCA mutant cancer\u201d. DNA Repair 107, 103209 (2021).","journal-title":"DNA Repair"},{"key":"1745_CR60","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41556-020-00624-3","volume":"23","author":"P Verma","year":"2021","unstructured":"Verma, P. et al. ALC1 links chromatin accessibility to PARP inhibitor response in homologous recombination-deficient cells. Nat. Cell Biol. 23, 160\u2013171 (2021).","journal-title":"Nat. Cell Biol."},{"key":"1745_CR61","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1158\/0008-5472.CAN-20-1602","volume":"81","author":"NJ Panzarino","year":"2021","unstructured":"Panzarino, N. J. et al. Replication gaps underlie BRCA deficiency and therapy response. Cancer Res. 81, 1388\u20131397 (2021).","journal-title":"Cancer Res."},{"key":"1745_CR62","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/s41576-022-00459-8","volume":"23","author":"R Pecori","year":"2022","unstructured":"Pecori, R., Di Giorgio, S., Paulo Lorenzo, J. & Nina Papavasiliou, F. Functions and consequences of AID\/APOBEC-mediated DNA and RNA deamination. Nat. Rev. Genet. 23, 505\u2013518 (2022).","journal-title":"Nat. Rev. Genet."},{"key":"1745_CR63","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.1093\/nar\/gkm372","volume":"35","author":"HS Pettersen","year":"2007","unstructured":"Pettersen, H. S. et al. Uracil-DNA glycosylases SMUG1 and UNG2 coordinate the initial steps of base excision repair by distinct mechanisms. Nucleic Acids Res. 35, 3879\u20133892 (2007).","journal-title":"Nucleic Acids Res."},{"key":"1745_CR64","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.cell.2018.10.055","volume":"176","author":"KN Mohni","year":"2019","unstructured":"Mohni, K. N. et al. HMCES maintains genome integrity by shielding abasic sites in single-strand DNA. Cell 176, 144\u2013153 (2019).","journal-title":"Cell"},{"key":"1745_CR65","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ads3227","volume":"11","author":"MJ Pena-Gomez","year":"2025","unstructured":"Pena-Gomez, M. J. et al. HMCES corrupts replication fork stability during base excision repair in homologous recombination-deficient cells. Sci. Adv. 11, eads3227 (2025).","journal-title":"Sci. Adv."},{"key":"1745_CR66","doi-asserted-by":"publisher","first-page":"3026","DOI":"10.1016\/j.molcel.2024.07.004","volume":"84","author":"YW Hanthi","year":"2024","unstructured":"Hanthi, Y. W. et al. RAD51 protects abasic sites to prevent replication fork breakage. Mol. Cell 84, 3026\u20133043 (2024).","journal-title":"Mol. Cell"},{"key":"1745_CR67","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1126\/science.abb4542","volume":"372","author":"K Fugger","year":"2021","unstructured":"Fugger, K. et al. Targeting the nucleotide salvage factor DNPH1 sensitizes BRCA-deficient cells to PARP inhibitors. Science 372, 156\u2013165 (2021).","journal-title":"Science"},{"key":"1745_CR68","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2022113190","volume":"42","author":"A Serrano-Benitez","year":"2023","unstructured":"Serrano-Benitez, A. et al. Unrepaired base excision repair intermediates in template DNA strands trigger replication fork collapse and PARP inhibitor sensitivity. EMBO J. 42, e113190 (2023).","journal-title":"EMBO J."},{"key":"1745_CR69","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.molcel.2025.01.031","volume":"85","author":"D Musiani","year":"2025","unstructured":"Musiani, D. et al. Uracil processing by SMUG1 in the absence of UNG triggers homologous recombination and selectively kills BRCA1\/2-deficient tumors. Mol. Cell 85, 1072\u20131084(2025).","journal-title":"Mol. Cell"},{"key":"1745_CR70","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1016\/j.molcel.2024.04.004","volume":"84","author":"S Saxena","year":"2024","unstructured":"Saxena, S. et al. Unprocessed genomic uracil as a source of DNA replication stress in cancer cells. Mol. Cell 84, 2036\u20132052 (2024).","journal-title":"Mol. Cell"},{"key":"1745_CR71","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adk2771","volume":"10","author":"AS Kawale","year":"2024","unstructured":"Kawale, A. S. et al. APOBEC3A induces DNA gaps through PRIMPOL and confers gap-associated therapeutic vulnerability. Sci. Adv. 10, eadk2771 (2024).","journal-title":"Sci. Adv."},{"key":"1745_CR72","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adu0437","volume":"11","author":"P Ortega","year":"2025","unstructured":"Ortega, P. et al. Mechanism of DNA replication fork breakage and PARP1 hyperactivation during replication catastrophe. Sci. Adv. 11, eadu0437 (2025).","journal-title":"Sci. Adv."},{"key":"1745_CR73","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1016\/j.molcel.2022.04.014","volume":"82","author":"JR Brickner","year":"2022","unstructured":"Brickner, J. R., Garzon, J. L. & Cimprich, K. A. Walking a tightrope: The complex balancing act of R-loops in genome stability. Mol. Cell 82, 2267\u20132297 (2022).","journal-title":"Mol. Cell"},{"key":"1745_CR74","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/ni.3558","volume":"17","author":"Q Chen","year":"2016","unstructured":"Chen, Q., Sun, L. & Chen, Z. J. Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing. Nat. Immunol. 17, 1142\u20131149 (2016).","journal-title":"Nat. Immunol."},{"key":"1745_CR75","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3389\/fimmu.2018.00847","volume":"9","author":"F Castro","year":"2018","unstructured":"Castro, F., Cardoso, A. P., Goncalves, R. M., Serre, K. & Oliveira, M. J. Interferon-gamma at the crossroads of tumor immune surveillance or evasion. Front. Immunol. 9, 847 (2018).","journal-title":"Front. Immunol."},{"key":"1745_CR76","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01924-6","volume":"23","author":"S Zhang","year":"2024","unstructured":"Zhang, S. et al. Aberrant R-loop-mediated immune evasion, cellular communication, and metabolic reprogramming affect cancer progression: a single-cell analysis. Mol. Cancer 23, 11 (2024).","journal-title":"Mol. Cancer"},{"key":"1745_CR77","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.devcel.2021.02.006","volume":"56","author":"JT Weinreb","year":"2021","unstructured":"Weinreb, J. T. et al. Excessive R-loops trigger an inflammatory cascade leading to increased HSPC production. Dev. Cell 56, 627\u2013640 (2021).","journal-title":"Dev. Cell"},{"key":"1745_CR78","doi-asserted-by":"publisher","unstructured":"He, Y. et al. NF-kappaB-induced R-loop accumulation and DNA damage select for nucleotide excision repair deficiencies in adult T cell leukemia. Proc. Natl Acad. Sci. USA https:\/\/doi.org\/10.1073\/pnas.2005568118 (2021).","DOI":"10.1073\/pnas.2005568118"},{"key":"1745_CR79","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2024.01.008","volume":"187","author":"G Leuzzi","year":"2024","unstructured":"Leuzzi, G. et al. SMARCAL1 is a dual regulator of innate immune signaling and PD-L1 expression that promotes tumor immune evasion. Cell 187, 861\u2013881(2024).","journal-title":"Cell"},{"key":"1745_CR80","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.ceb.2010.07.013","volume":"22","author":"VG Gorgoulis","year":"2010","unstructured":"Gorgoulis, V. G. & Halazonetis, T. D. Oncogene-induced senescence: the bright and dark side of the response. Curr. Opin. Cell Biol. 22, 816\u2013827 (2010).","journal-title":"Curr. Opin. Cell Biol."},{"key":"1745_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8094","volume":"6","author":"K Miron","year":"2015","unstructured":"Miron, K., Golan-Lev, T., Dvir, R., Ben-David, E. & Kerem, B. Oncogenes create a unique landscape of fragile sites. Nat. Commun. 6, 7094 (2015).","journal-title":"Nat. Commun."},{"key":"1745_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13087","volume":"7","author":"P Kotsantis","year":"2016","unstructured":"Kotsantis, P. et al. Increased global transcription activity as a mechanism of replication stress in cancer. Nat. Commun. 7, 13087 (2016).","journal-title":"Nat. Commun."},{"key":"1745_CR83","doi-asserted-by":"publisher","unstructured":"Dominguez-Sola, D. & Gautier, J. MYC and the control of DNA replication. Cold Spring Harb. Perspect. Med. https:\/\/doi.org\/10.1101\/cshperspect.a014423 (2014).","DOI":"10.1101\/cshperspect.a014423"},{"key":"1745_CR84","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.celrep.2013.03.004","volume":"3","author":"KM Aird","year":"2013","unstructured":"Aird, K. M. et al. Suppression of nucleotide metabolism underlies the establishment and maintenance of oncogene-induced senescence. Cell Rep. 3, 1252\u20131265 (2013).","journal-title":"Cell Rep."},{"key":"1745_CR85","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.devcel.2011.10.010","volume":"21","author":"Z Tu","year":"2011","unstructured":"Tu, Z. et al. Oncogenic RAS regulates BRIP1 expression to induce dissociation of BRCA1 from chromatin, inhibit DNA repair, and promote senescence. Dev. Cell 21, 1077\u20131091 (2011).","journal-title":"Dev. Cell"},{"key":"1745_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2025.152203","volume":"776","author":"JJ Park","year":"2025","unstructured":"Park, J. J. et al. Loss of DNA replication fork protection by TIMELESS degradation supports oncogene-induced senescence. Biochem. Biophys. Res. Commun. 776, 152203 (2025).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1745_CR87","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1126\/science.aao3172","volume":"358","author":"K Somyajit","year":"2017","unstructured":"Somyajit, K. et al. Redox-sensitive alteration of replisome architecture safeguards genome integrity. Science 358, 797\u2013802 (2017).","journal-title":"Science"},{"key":"1745_CR88","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39867-7","volume":"14","author":"P Smith","year":"2023","unstructured":"Smith, P. et al. The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma. Nat. Commun. 14, 4387 (2023).","journal-title":"Nat. Commun."},{"key":"1745_CR89","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"Cancer Genome Atlas Research Network.","year":"2011","unstructured":"Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609\u2013615 (2011).","journal-title":"Nature"},{"key":"1745_CR90","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1158\/0008-5472.CAN-13-2247","volume":"74","author":"AM Karst","year":"2014","unstructured":"Karst, A. M. et al. Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers. Cancer Res. 74, 1141\u20131152 (2014).","journal-title":"Cancer Res."},{"key":"1745_CR91","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1158\/2159-8290.CD-23-0954","volume":"14","author":"C Dietrich","year":"2024","unstructured":"Dietrich, C. et al. INX-315, a selective CDK2 inhibitor, induces cell cycle arrest and senescence in solid tumors. Cancer Discov. 14, 446\u2013467 (2024).","journal-title":"Cancer Discov."},{"key":"1745_CR92","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1158\/0008-5472.CAN-24-2219","volume":"85","author":"T Saleh","year":"2025","unstructured":"Saleh, T., Greenberg, E. F., Faber, A. C., Harada, H. & Gewirtz, D. A. A critical appraisal of the utility of targeting therapy-induced senescence for cancer treatment. Cancer Res. 85, 1755\u20131768 (2025).","journal-title":"Cancer Res."},{"key":"1745_CR93","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1101\/gad.343129.120","volume":"34","author":"J Birch","year":"2020","unstructured":"Birch, J. & Gil, J. Senescence and the SASP: many therapeutic avenues. Genes Dev. 34, 1565\u20131576 (2020).","journal-title":"Genes Dev."},{"key":"1745_CR94","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.semcancer.2022.02.005","volume":"86","author":"L Chibaya","year":"2022","unstructured":"Chibaya, L., Snyder, J. & Ruscetti, M. Senescence and the tumor-immune landscape: Implications for cancer immunotherapy. Semin. Cancer Biol. 86, 827\u2013845 (2022).","journal-title":"Semin. Cancer Biol."},{"key":"1745_CR95","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/nature05541","volume":"445","author":"A Ventura","year":"2007","unstructured":"Ventura, A. et al. Restoration of p53 function leads to tumour regression in vivo. Nature 445, 661\u2013665 (2007).","journal-title":"Nature"},{"key":"1745_CR96","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1158\/0008-5472.CAN-18-3437","volume":"79","author":"T Saleh","year":"2019","unstructured":"Saleh, T., Tyutyunyk-Massey, L. & Gewirtz, D. A. Tumor cell escape from therapy-induced senescence as a model of disease recurrence after dormancy. Cancer Res. 79, 1044\u20131046 (2019).","journal-title":"Cancer Res."},{"key":"1745_CR97","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02310-0","volume":"24","author":"E Bajtai","year":"2025","unstructured":"Bajtai, E. et al. Therapy-induced senescence is a transient drug resistance mechanism in breast cancer. Mol. Cancer 24, 128 (2025).","journal-title":"Mol. Cancer"},{"key":"1745_CR98","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/imm.12036","volume":"138","author":"D Lindau","year":"2013","unstructured":"Lindau, D., Gielen, P., Kroesen, M., Wesseling, P. & Adema, G. J. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology 138, 105\u2013115 (2013).","journal-title":"Immunology"},{"key":"1745_CR99","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.3389\/fonc.2019.01370","volume":"9","author":"S Quintero-Fabian","year":"2019","unstructured":"Quintero-Fabian, S. et al. Role of matrix metalloproteinases in angiogenesis and cancer. Front. Oncol. 9, 1370 (2019).","journal-title":"Front. Oncol."},{"key":"1745_CR100","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nature25167","volume":"553","author":"M Milanovic","year":"2018","unstructured":"Milanovic, M. et al. Senescence-associated reprogramming promotes cancer stemness. Nature 553, 96\u2013100 (2018).","journal-title":"Nature"},{"key":"1745_CR101","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1101\/gad.17276711","volume":"25","author":"Y Chien","year":"2011","unstructured":"Chien, Y. et al. Control of the senescence-associated secretory phenotype by NF-kappaB promotes senescence and enhances chemosensitivity. Genes Dev. 25, 2125\u20132136 (2011).","journal-title":"Genes Dev."},{"key":"1745_CR102","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41392-024-01757-9","volume":"9","author":"Q Guo","year":"2024","unstructured":"Guo, Q. et al. NF-kappaB in biology and targeted therapy: new insights and translational implications. Signal Transduct. Target. Ther. 9, 53 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1745_CR103","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/cr.2010.179","volume":"21","author":"S Miyamoto","year":"2011","unstructured":"Miyamoto, S. Nuclear initiated NF-kappaB signaling: NEMO and ATM take center stage. Cell Res. 21, 116\u2013130 (2011).","journal-title":"Cell Res."},{"key":"1745_CR104","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1126\/science.1121513","volume":"311","author":"ZH Wu","year":"2006","unstructured":"Wu, Z. H., Shi, Y., Tibbetts, R. S. & Miyamoto, S. Molecular linkage between the kinase ATM and NF-kappaB signaling in response to genotoxic stimuli. Science 311, 1141\u20131146 (2006).","journal-title":"Science"},{"key":"1745_CR105","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0092-8674(03)00895-X","volume":"115","author":"TT Huang","year":"2003","unstructured":"Huang, T. T., Wuerzberger-Davis, S. M., Wu, Z. H. & Miyamoto, S. Sequential modification of NEMO\/IKKgamma by SUMO-1 and ubiquitin mediates NF-kappaB activation by genotoxic stress. Cell 115, 565\u2013576 (2003).","journal-title":"Cell"},{"key":"1745_CR106","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.molcel.2009.09.032","volume":"36","author":"M Stilmann","year":"2009","unstructured":"Stilmann, M. et al. A nuclear poly(ADP-ribose)-dependent signalosome confers DNA damage-induced IkappaB kinase activation. Mol. Cell 36, 365\u2013378 (2009).","journal-title":"Mol. Cell"},{"key":"1745_CR107","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1158\/2326-6066.CIR-14-0112","volume":"2","author":"Y Xia","year":"2014","unstructured":"Xia, Y., Shen, S. & Verma, I. M. NF-kappaB, an active player in human cancers. Cancer Immunol. Res. 2, 823\u2013830 (2014).","journal-title":"Cancer Immunol. Res."},{"key":"1745_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112185","volume":"42","author":"L Zhang","year":"2023","unstructured":"Zhang, L. et al. NF-kappaB activation enhances STING signaling by altering microtubule-mediated STING trafficking. Cell Rep. 42, 112185 (2023).","journal-title":"Cell Rep."},{"key":"1745_CR109","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2399-y","volume":"11","author":"D Verzella","year":"2020","unstructured":"Verzella, D. et al. Life, death, and autophagy in cancer: NF-kappaB turns up everywhere. Cell Death Dis. 11, 210 (2020).","journal-title":"Cell Death Dis."},{"key":"1745_CR110","doi-asserted-by":"publisher","first-page":"5299","DOI":"10.1128\/MCB.21.16.5299-5305.2001","volume":"21","author":"O Micheau","year":"2001","unstructured":"Micheau, O., Lens, S., Gaide, O., Alevizopoulos, K. & Tschopp, J. NF-kappaB signals induce the expression of c-FLIP. Mol. Cell Biol. 21, 5299\u20135305 (2001).","journal-title":"Mol. Cell Biol."},{"key":"1745_CR111","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/sj.onc.1209122","volume":"25","author":"DB Longley","year":"2006","unstructured":"Longley, D. B. et al. c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene 25, 838\u2013848 (2006).","journal-title":"Oncogene"},{"key":"1745_CR112","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1038\/s42003-025-09084-7","volume":"8","author":"A Khan","year":"2025","unstructured":"Khan, A. et al. TIPIN coordinates ATM-dependent checkpoint and NF-kappaB signaling to counteract DNA replication damage from topoisomerase inhibition. Commun. Biol. 8, 1683 (2025).","journal-title":"Commun. Biol."},{"key":"1745_CR113","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S0092-8674(00)80405-5","volume":"91","author":"SR Datta","year":"1997","unstructured":"Datta, S. R. et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91, 231\u2013241 (1997).","journal-title":"Cell"},{"key":"1745_CR114","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1128\/MCB.21.3.893-901.2001","volume":"21","author":"AH Kim","year":"2001","unstructured":"Kim, A. H., Khursigara, G., Sun, X., Franke, T. F. & Chao, M. V. Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol. Cell Biol. 21, 893\u2013901 (2001).","journal-title":"Mol. Cell Biol."},{"key":"1745_CR115","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1002\/ijc.24748","volume":"125","author":"D Bai","year":"2009","unstructured":"Bai, D., Ueno, L. & Vogt, P. K. Akt-mediated regulation of NFkappaB and the essentialness of NFkappaB for the oncogenicity of PI3K and Akt. Int. J. Cancer 125, 2863\u20132870 (2009).","journal-title":"Int. J. Cancer"},{"key":"1745_CR116","doi-asserted-by":"publisher","first-page":"7785","DOI":"10.1073\/pnas.0703423105","volume":"105","author":"KA Boehme","year":"2008","unstructured":"Boehme, K. A., Kulikov, R. & Blattner, C. p53 stabilization in response to DNA damage requires Akt\/PKB and DNA-PK. Proc. Natl Acad. Sci. USA 105, 7785\u20137790 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1745_CR117","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1158\/1541-7786.MCR-11-0592","volume":"10","author":"M Toulany","year":"2012","unstructured":"Toulany, M. et al. Akt promotes post-irradiation survival of human tumor cells through initiation, progression, and termination of DNA-PKcs-dependent DNA double-strand break repair. Mol. Cancer Res. 10, 945\u2013957 (2012).","journal-title":"Mol. Cancer Res."},{"key":"1745_CR118","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.molcel.2017.05.001","volume":"66","author":"L Toledo","year":"2017","unstructured":"Toledo, L., Neelsen, K. J. & Lukas, J. Replication catastrophe: when a checkpoint fails because of exhaustion. Mol. Cell 66, 735\u2013749 (2017).","journal-title":"Mol. Cell"},{"key":"1745_CR119","doi-asserted-by":"publisher","unstructured":"Patel, J. A. et al. Replisome dysfunction upon inducible TIMELESS degradation synergizes with ATR inhibition to trigger replication catastrophe. Nucleic Acids Res. https:\/\/doi.org\/10.1093\/nar\/gkad363(2023).","DOI":"10.1093\/nar\/gkad363"},{"key":"1745_CR120","doi-asserted-by":"publisher","unstructured":"Moeglin, E. et al. Uniform widespread nuclear phosphorylation of histone H2AX is an indicator of lethal DNA replication stress. Cancers https:\/\/doi.org\/10.3390\/cancers11030355(2019).","DOI":"10.3390\/cancers11030355"},{"key":"1745_CR121","doi-asserted-by":"publisher","DOI":"10.1002\/bies.201900127","volume":"41","author":"MC Liebl","year":"2019","unstructured":"Liebl, M. C. & Hofmann, T. G. Cell fate regulation upon DNA damage: p53 serine 46 kinases pave the cell death road. Bioessays 41, e1900127 (2019).","journal-title":"Bioessays"},{"key":"1745_CR122","doi-asserted-by":"publisher","first-page":"6245","DOI":"10.1038\/onc.2008.301","volume":"27","author":"DN Dhanasekaran","year":"2008","unstructured":"Dhanasekaran, D. N. & Reddy, E. P. JNK signaling in apoptosis. Oncogene 27, 6245\u20136251 (2008).","journal-title":"Oncogene"},{"key":"1745_CR123","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/ncb714","volume":"4","author":"G D\u2019Orazi","year":"2002","unstructured":"D\u2019Orazi, G. et al. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat. Cell Biol. 4, 11\u201319 (2002).","journal-title":"Nat. Cell Biol."},{"key":"1745_CR124","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/ncb1743","volume":"10","author":"M Winter","year":"2008","unstructured":"Winter, M. et al. Control of HIPK2 stability by ubiquitin ligase Siah-1 and checkpoint kinases ATM and ATR. Nat. Cell Biol. 10, 812\u2013824 (2008).","journal-title":"Nat. Cell Biol."},{"key":"1745_CR125","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.cell.2011.02.023","volume":"145","author":"S Biton","year":"2011","unstructured":"Biton, S. & Ashkenazi, A. NEMO and RIP1 control cell fate in response to extensive DNA damage via TNF-alpha feedforward signaling. Cell 145, 92\u2013103 (2011).","journal-title":"Cell"},{"key":"1745_CR126","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/s41580-023-00623-w","volume":"24","author":"J Clucas","year":"2023","unstructured":"Clucas, J. & Meier, P. Roles of RIPK1 as a stress sentinel coordinating cell survival and immunogenic cell death. Nat. Rev. Mol. Cell Biol. 24, 835\u2013852 (2023).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1745_CR127","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1111\/bph.12416","volume":"171","author":"AA Fatokun","year":"2014","unstructured":"Fatokun, A. A., Dawson, V. L. & Dawson, T. M. Parthanatos: mitochondrial-linked mechanisms and therapeutic opportunities. Br J. Pharmacol. 171, 2000\u20132016 (2014).","journal-title":"Br J. Pharmacol."},{"key":"1745_CR128","doi-asserted-by":"publisher","first-page":"ra20","DOI":"10.1126\/scisignal.2000902","volume":"4","author":"Y Wang","year":"2011","unstructured":"Wang, Y. et al. Poly(ADP-ribose) (PAR) binding to apoptosis-inducing factor is critical for PAR polymerase-1-dependent cell death (parthanatos). Sci. Signal 4, ra20 (2011).","journal-title":"Sci. Signal"},{"key":"1745_CR129","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/nrm3115","volume":"12","author":"I Vitale","year":"2011","unstructured":"Vitale, I., Galluzzi, L., Castedo, M. & Kroemer, G. Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat. Rev. Mol. Cell Biol. 12, 385\u2013392 (2011).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1745_CR130","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15981","volume":"8","author":"PM Schoonen","year":"2017","unstructured":"Schoonen, P. M. et al. Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells. Nat. Commun. 8, 15981 (2017).","journal-title":"Nat. Commun."},{"key":"1745_CR131","doi-asserted-by":"publisher","first-page":"6143","DOI":"10.1038\/s41388-021-02003-0","volume":"40","author":"S Di Giulio","year":"2021","unstructured":"Di Giulio, S. et al. A combination of PARP and CHK1 inhibitors efficiently antagonizes MYCN-driven tumors. Oncogene 40, 6143\u20136152 (2021).","journal-title":"Oncogene"},{"key":"1745_CR132","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108096","volume":"32","author":"MD Rainey","year":"2020","unstructured":"Rainey, M. D. et al. ATR restrains DNA synthesis and mitotic catastrophe in response to CDC7 inhibition. Cell Rep. 32, 108096 (2020).","journal-title":"Cell Rep."},{"key":"1745_CR133","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1002\/1878-0261.12573","volume":"13","author":"PM Schoonen","year":"2019","unstructured":"Schoonen, P. M. et al. Premature mitotic entry induced by ATR inhibition potentiates olaparib inhibition-mediated genomic instability, inflammatory signaling, and cytotoxicity in BRCA2-deficient cancer cells. Mol. Oncol. 13, 2422\u20132440 (2019).","journal-title":"Mol. Oncol."},{"key":"1745_CR134","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/s41568-022-00450-9","volume":"22","author":"L Wang","year":"2022","unstructured":"Wang, L., Lankhorst, L. & Bernards, R. Exploiting senescence for the treatment of cancer. Nat. Rev. Cancer 22, 340\u2013355 (2022).","journal-title":"Nat. Rev. Cancer"},{"key":"1745_CR135","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1158\/2159-8290.CD-16-0241","volume":"7","author":"M Demaria","year":"2017","unstructured":"Demaria, M. et al. Cellular senescence promotes adverse effects of chemotherapy and cancer relapse. Cancer Discov. 7, 165\u2013176 (2017).","journal-title":"Cancer Discov."},{"key":"1745_CR136","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1002\/1878-0261.12761","volume":"14","author":"T Saleh","year":"2020","unstructured":"Saleh, T. et al. Clearance of therapy-induced senescent tumor cells by the senolytic ABT-263 via interference with BCL-X(L) -BAX interaction. Mol. Oncol. 14, 2504\u20132519 (2020).","journal-title":"Mol. Oncol."},{"key":"1745_CR137","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1038\/s41418-020-0564-6","volume":"27","author":"A Shahbandi","year":"2020","unstructured":"Shahbandi, A. et al. BH3 mimetics selectively eliminate chemotherapy-induced senescent cells and improve response in TP53 wild-type breast cancer. Cell Death Differ. 27, 3097\u20133116 (2020).","journal-title":"Cell Death Differ."},{"key":"1745_CR138","volume":"7","author":"MM Hoque","year":"2024","unstructured":"Hoque, M. M., Iida, Y., Kotani, H. & Harada, M. Senolysis of gemcitabine-induced senescent human pancreatic cancer cells. Cancer Rep. 7, e2075 (2024).","journal-title":"Cancer Rep."},{"key":"1745_CR139","doi-asserted-by":"publisher","unstructured":"Schwarzenbach, C. et al. Targeting c-IAP1, c-IAP2, and Bcl-2 eliminates senescent glioblastoma cells following temozolomide treatment. Cancers https:\/\/doi.org\/10.3390\/cancers13143585 (2021).","DOI":"10.3390\/cancers13143585"},{"key":"1745_CR140","doi-asserted-by":"publisher","unstructured":"Beltzig, L., Christmann, M. & Kaina, B. Abrogation of cellular senescence induced by temozolomide in glioblastoma cells: search for senolytics. Cells https:\/\/doi.org\/10.3390\/cells11162588 (2022).","DOI":"10.3390\/cells11162588"},{"key":"1745_CR141","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1158\/1541-7786.MCR-21-0029","volume":"20","author":"M Rahman","year":"2022","unstructured":"Rahman, M. et al. Selective vulnerability of senescent glioblastoma cells to BCL-XL inhibition. Mol. Cancer Res. 20, 938\u2013948 (2022).","journal-title":"Mol. Cancer Res."},{"key":"1745_CR142","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10460-1","volume":"10","author":"H Fleury","year":"2019","unstructured":"Fleury, H. et al. Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence. Nat. Commun. 10, 2556 (2019).","journal-title":"Nat. Commun."},{"key":"1745_CR143","doi-asserted-by":"publisher","unstructured":"Malaquin, N. et al. DNA damage- but not enzalutamide-induced senescence in prostate cancer promotes senolytic Bcl-xL inhibitor sensitivity. Cells https:\/\/doi.org\/10.3390\/cells9071593 (2020).","DOI":"10.3390\/cells9071593"},{"key":"1745_CR144","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s44446-025-00034-2","volume":"33","author":"S Almudimeegh","year":"2025","unstructured":"Almudimeegh, S. et al. Talazoparib and radiation enhance the senolytic efficacy of venetoclax in therapy-induced senescent triple-negative breast cancer cells. Saudi Pharm. J. 33, 31 (2025).","journal-title":"Saudi Pharm. J."},{"key":"1745_CR145","doi-asserted-by":"publisher","unstructured":"Softah, A. et al. The combination of radiation with PARP inhibition enhances senescence and sensitivity to the senolytic, navitoclax, in triple negative breast tumor cells. Biomedicines https:\/\/doi.org\/10.3390\/biomedicines11113066 (2023).","DOI":"10.3390\/biomedicines11113066"},{"key":"1745_CR146","doi-asserted-by":"publisher","unstructured":"Huart, C. et al. Taking advantage of the senescence-promoting effect of olaparib after X-ray and proton irradiation using the senolytic drug, ABT-263. Cancers https:\/\/doi.org\/10.3390\/cancers14061460 (2022).","DOI":"10.3390\/cancers14061460"},{"key":"1745_CR147","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1007\/s10637-014-0116-3","volume":"32","author":"G Vlahovic","year":"2014","unstructured":"Vlahovic, G. et al. A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin\/paclitaxel in the treatment of patients with solid tumors. Invest. New Drugs 32, 976\u2013984 (2014).","journal-title":"Invest. New Drugs"},{"key":"1745_CR148","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1182\/blood-2011-10-387399","volume":"119","author":"SM Schoenwaelder","year":"2012","unstructured":"Schoenwaelder, S. M. & Jackson, S. P. Bcl-xL-inhibitory BH3 mimetics (ABT-737 or ABT-263) and the modulation of cytosolic calcium flux and platelet function. Blood 119, 1320\u20131321 (2012).","journal-title":"Blood"},{"key":"1745_CR149","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13045-015-0224-3","volume":"8","author":"S Cang","year":"2015","unstructured":"Cang, S., Iragavarapu, C., Savooji, J., Song, Y. & Liu, D. ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development. J. Hematol. Oncol. 8, 129 (2015).","journal-title":"J. Hematol. Oncol."},{"key":"1745_CR150","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.celrep.2017.09.085","volume":"21","author":"L Wang","year":"2017","unstructured":"Wang, L. et al. High-throughput functional genetic and compound screens identify targets for senescence induction in cancer. Cell Rep. 21, 773\u2013783 (2017).","journal-title":"Cell Rep."},{"key":"1745_CR151","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-016-0234-y","volume":"9","author":"MN Abed","year":"2016","unstructured":"Abed, M. N., Abdullah, M. I. & Richardson, A. Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells. J. Ovarian Res. 9, 25 (2016).","journal-title":"J. Ovarian Res."},{"key":"1745_CR152","doi-asserted-by":"publisher","unstructured":"Mu\u00f1oz-Esp\u00edn, D. et al. A versatile drug delivery system targeting senescent cells. EMBO Mol. Med. https:\/\/doi.org\/10.15252\/emmm.201809355 (2018).","DOI":"10.15252\/emmm.201809355"},{"key":"1745_CR153","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13142","volume":"19","author":"E Gonz\u00e1lez-Gualda","year":"2020","unstructured":"Gonz\u00e1lez-Gualda, E. et al. Galacto-conjugation of Navitoclax as an efficient strategy to increase senolytic specificity and reduce platelet toxicity. Aging Cell 19, e13142 (2020).","journal-title":"Aging Cell"},{"key":"1745_CR154","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15838-0","volume":"11","author":"Y He","year":"2020","unstructured":"He, Y. et al. Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity. Nat. Commun. 11, 1996 (2020).","journal-title":"Nat. Commun."},{"key":"1745_CR155","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17127-2","volume":"11","author":"H Kim","year":"2020","unstructured":"Kim, H. et al. Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models. Nat. Commun. 11, 3726 (2020).","journal-title":"Nat. Commun."},{"key":"1745_CR156","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1158\/1078-0432.CCR-16-2273","volume":"23","author":"H Kim","year":"2017","unstructured":"Kim, H. et al. Targeting the ATR\/CHK1 axis with PARP inhibition results in tumor regression in BRCA-mutant ovarian cancer models. Clin. Cancer Res. 23, 3097\u20133108 (2017).","journal-title":"Clin. Cancer Res."},{"key":"1745_CR157","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1101\/gad.290957.116","volume":"31","author":"SA Yazinski","year":"2017","unstructured":"Yazinski, S. A. et al. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells. Genes Dev. 31, 318\u2013332 (2017).","journal-title":"Genes Dev."},{"key":"1745_CR158","doi-asserted-by":"publisher","unstructured":"Biega\u0142a, \u0141., Gajek, A., Marczak, A. & Rogalska, A. Olaparib-resistant BRCA2(MUT) ovarian cancer cells with restored BRCA2 abrogate olaparib-induced DNA damage and G2\/M arrest controlled by the ATR\/CHK1 pathway for survival. Cells https:\/\/doi.org\/10.3390\/cells12071038 (2023).","DOI":"10.3390\/cells12071038"},{"key":"1745_CR159","doi-asserted-by":"publisher","unstructured":"Gralewska, P. et al. PARP inhibition increases the reliance on ATR\/CHK1 checkpoint signaling leading to synthetic lethality-an alternative treatment strategy for epithelial ovarian cancer cells independent from HR effectiveness. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms21249715 (2020).","DOI":"10.3390\/ijms21249715"},{"key":"1745_CR160","doi-asserted-by":"publisher","unstructured":"Gralewska, P., Gajek, A., Rybaczek, D., Marczak, A. & Rogalska, A. The influence of PARP, ATR, CHK1 inhibitors on premature mitotic entry and genomic instability in high-grade serous BRCA(MUT) and BRCA(WT) ovarian cancer cells. Cells https:\/\/doi.org\/10.3390\/cells11121889 (2022).","DOI":"10.3390\/cells11121889"},{"key":"1745_CR161","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202501916","volume":"12","author":"Y Gao","year":"2025","unstructured":"Gao, Y. et al. Novel ATR\/PARP1 dual inhibitors demonstrate synergistic antitumor efficacy in triple-negative breast cancer models. Adv. Sci. 12, e01916 (2025).","journal-title":"Adv. Sci."},{"key":"1745_CR162","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.109978","volume":"27","author":"H Xu","year":"2024","unstructured":"Xu, H. et al. CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer. iScience 27, 109978 (2024).","journal-title":"iScience"},{"key":"1745_CR163","doi-asserted-by":"publisher","unstructured":"Mahdi, H. et al. Ceralasertib-mediated ATR inhibition combined with olaparib in advanced cancers harboring DNA damage response and repair alterations (olaparib combinations). JCO Precis. Oncol. https:\/\/doi.org\/10.1200\/po.20.00439 (2021).","DOI":"10.1200\/po.20.00439"},{"key":"1745_CR164","doi-asserted-by":"publisher","first-page":"4751","DOI":"10.1158\/1078-0432.CCR-23-1696","volume":"29","author":"A Ring","year":"2023","unstructured":"Ring, A. et al. Olaparib and ceralasertib (AZD6738) in patients with triple-negative advanced breast cancer: results from cohort E of the plasmaMATCH trial (CRUK\/15\/010). Clin. Cancer Res. 29, 4751\u20134759 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1745_CR165","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1158\/1078-0432.CCR-22-2444","volume":"29","author":"SL Wethington","year":"2023","unstructured":"Wethington, S. L. et al. Combination ATR (ceralasertib) and PARP (olaparib) inhibitor (CAPRI) trial in acquired PARP inhibitor-resistant homologous recombination-deficient ovarian cancer. Clin. Cancer Res. 29, 2800\u20132807 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1745_CR166","doi-asserted-by":"publisher","first-page":"4710","DOI":"10.1158\/1078-0432.CCR-21-1279","volume":"27","author":"KT Do","year":"2021","unstructured":"Do, K. T. et al. Phase 1 combination study of the CHK1 inhibitor prexasertib and the PARP inhibitor olaparib in high-grade serous ovarian cancer and other solid tumors. Clin. Cancer Res. 27, 4710\u20134716 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1745_CR167","doi-asserted-by":"publisher","unstructured":"Li, X. & Zou, L. BRCAness, DNA gaps, and gain and loss of PARP inhibitor-induced synthetic lethality. J. Clin. Invest. https:\/\/doi.org\/10.1172\/JCI181062 (2024).","DOI":"10.1172\/JCI181062"},{"key":"1745_CR168","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1158\/2159-8290.CD-18-1020","volume":"9","author":"T Sen","year":"2019","unstructured":"Sen, T. et al. Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer. Cancer Discov. 9, 646\u2013661 (2019).","journal-title":"Cancer Discov."},{"key":"1745_CR169","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-38534-6","volume":"9","author":"Z Wang","year":"2019","unstructured":"Wang, Z. et al. Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models. Sci. Rep. 9, 1853 (2019).","journal-title":"Sci. Rep."},{"key":"1745_CR170","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1016\/j.celrep.2018.11.054","volume":"25","author":"L Ding","year":"2018","unstructured":"Ding, L. et al. PARP inhibition elicits STING-dependent antitumor immunity in Brca1-deficient ovarian cancer. Cell Rep. 25, 2972\u20132980 (2018).","journal-title":"Cell Rep."},{"key":"1745_CR171","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1158\/0008-5472.CAN-18-1003","volume":"79","author":"J Shen","year":"2019","unstructured":"Shen, J. et al. PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness. Cancer Res. 79, 311\u2013319 (2019).","journal-title":"Cancer Res."},{"key":"1745_CR172","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","volume":"23","author":"S Jiao","year":"2017","unstructured":"Jiao, S. et al. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin. Cancer Res. 23, 3711\u20133720 (2017).","journal-title":"Clin. Cancer Res."},{"key":"1745_CR173","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01883-9","volume":"8","author":"H Sato","year":"2017","unstructured":"Sato, H. et al. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. Nat. Commun. 8, 1751 (2017).","journal-title":"Nat. Commun."},{"key":"1745_CR174","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1158\/2326-6066.CIR-15-0044","volume":"3","author":"T Higuchi","year":"2015","unstructured":"Higuchi, T. et al. CTLA-4 blockade synergizes therapeutically with PARP inhibition in BRCA1-deficient ovarian cancer. Cancer Immunol. Res. 3, 1257\u20131268 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"1745_CR175","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1001\/jamaoncol.2019.1048","volume":"5","author":"PA Konstantinopoulos","year":"2019","unstructured":"Konstantinopoulos, P. A. et al. Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncol. 5, 1141\u20131149 (2019).","journal-title":"JAMA Oncol."},{"key":"1745_CR176","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaoncol.2019.1029","volume":"5","author":"S Vinayak","year":"2019","unstructured":"Vinayak, S. et al. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol. 5, 1132\u20131140 (2019).","journal-title":"JAMA Oncol."},{"key":"1745_CR177","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/S1470-2045(20)30324-7","volume":"21","author":"SM Domchek","year":"2020","unstructured":"Domchek, S. M. et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1\/2, basket study. Lancet Oncol. 21, 1155\u20131164 (2020).","journal-title":"Lancet Oncol."},{"key":"1745_CR178","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S1470-2045(22)00369-2","volume":"23","author":"KA Reiss","year":"2022","unstructured":"Reiss, K. A. et al. Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b\/2 trial. Lancet Oncol. 23, 1009\u20131020 (2022).","journal-title":"Lancet Oncol."},{"key":"1745_CR179","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.pharmthera.2014.05.007","volume":"144","author":"L Bai","year":"2014","unstructured":"Bai, L., Smith, D. C. & Wang, S. Small-molecule SMAC mimetics as new cancer therapeutics. Pharmacol. Ther. 144, 82\u201395 (2014).","journal-title":"Pharmacol. Ther."},{"key":"1745_CR180","doi-asserted-by":"publisher","unstructured":"Singh, T. et al. Efficacy of birinapant in combination with carboplatin in targeting platinum\u2011resistant epithelial ovarian cancers. Int. J. Oncol. https:\/\/doi.org\/10.3892\/ijo.2022.5325 (2022).","DOI":"10.3892\/ijo.2022.5325"},{"key":"1745_CR181","doi-asserted-by":"publisher","unstructured":"Noonan, A. M. et al. Matrix drug screen identifies synergistic drug combinations to augment SMAC mimetic activity in ovarian cancer. Cancers https:\/\/doi.org\/10.3390\/cancers12123784(2020).","DOI":"10.3390\/cancers12123784"},{"key":"1745_CR182","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s10495-020-01604-6","volume":"25","author":"C Yang","year":"2020","unstructured":"Yang, C. et al. Doxorubicin sensitizes cancer cells to Smac mimetic via synergistic activation of the CYLD\/RIPK1\/FADD\/caspase-8-dependent apoptosis. Apoptosis 25, 441\u2013455 (2020).","journal-title":"Apoptosis"},{"key":"1745_CR183","doi-asserted-by":"crossref","unstructured":"Petersen, S. L. et al. Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 12, 445\u2013456 (2007).","DOI":"10.1016\/j.ccr.2007.08.029"},{"key":"1745_CR184","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ejca.2022.12.015","volume":"183","author":"Y Tao","year":"2023","unstructured":"Tao, Y. et al. Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial. Eur. J. Cancer 183, 24\u201337 (2023).","journal-title":"Eur. J. Cancer"},{"key":"1745_CR185","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/cncr.29783","volume":"122","author":"AM Noonan","year":"2016","unstructured":"Noonan, A. M. et al. Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer. Cancer 122, 588\u2013597 (2016).","journal-title":"Cancer"}],"container-title":["Experimental &amp; Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01745-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01745-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01745-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T13:29:13Z","timestamp":1782912553000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01745-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":185,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["1745"],"URL":"https:\/\/doi.org\/10.1038\/s12276-026-01745-9","relation":{},"ISSN":["2092-6413"],"issn-type":[{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"assertion":[{"value":"20 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}